This site is intended for U.S. healthcare professionals.
Menu
Close
Menu
Close
Infusion Rates
- Patients must have commercial insurance to be eligible
- Patients are not eligible if they are enrolled in a state or federally funded insurance program
Download co-pay brochurePDF
TERMS AND CONDITIONS FOR PATIENTS
By using this co-pay card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:
- Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veterans Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
- Patient must have private insurance. Offer is not valid for cash paying patients. The value of this co-pay card is limited to a maximum of $12,500 per calendar year or the cost of patient co-pay in a 12-month period, whichever is less.
- This co-pay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
- You must deduct the value of this co-pay card from any reimbursem*nt request submitted to your private insurance plan, either directly by you or on your behalf.
- You are responsible for reporting use of the co-pay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
- Patient must be 2 years of age or older to be eligible for the co-pay benefit.
- Co-pay card cannot be combined with any other savings, free trial or similar offer for the specified prescription.
- Co-pay card will be accepted only at participating pharmacies.
- If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer.
- This co-pay card is not health insurance.
- Offer good only in the U.S. and Puerto Rico.
- Co-pay card is limited to 1 per person during this offering period and is not transferable.
- A co-pay card may not be redeemed more than once per 13 days per patient.
- No other purchase is necessary.
- No membership fee.
- Data related to your redemption of the co-pay card may be collected, analyzed, and shared with Pfizer for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
- Pfizer reserves the right to rescind, revoke or amend this offer without notice.
- Offer expires 12/31/2024.
For more information, call 1-866-642-7606, visit Panzyga Co-Pay Program
https://panzyga.pfizerpro.com/support/co-pay-program-for-patients or write:
P.O. Box 6875
Bridgewater, NJ 08807
- Materials
- Videos
- CIDP Warranty Program
- Pfizer PANZYGA Co-Pay Program for patients
- Pfizer IGuideTM
- Ig Companion patient mobile app
- Frequently asked questions
- Request a representative
To report an adverse event, please call 1-800-438-1985
Pfizer for Professionals 1-800-505-4426 This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only. © 2024Pfizer Inc. All rights reserved.
PP-PAN-USA-0828
PP-PAN-USA-0594
- Thrombosis may occur with immune globulin intravenous (IGIV) products, including PANZYGA. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
- Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IGIV products, including PANZYGA. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. PANZYGA does not contain sucrose.
- For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer PANZYGA at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [see Full Prescribing Information, Warnings and Precautions (5.2, 5.4)]
![PANZYGA® (Immune Globulin Intravenous (Human)-ifas, 10% solution) | Pfizer PANZYGA Co-Pay Program For Patients (1) PANZYGA® (Immune Globulin Intravenous (Human)-ifas, 10% solution) | Pfizer PANZYGA Co-Pay Program For Patients (1)](https://i0.wp.com/panzyga.pfizerpro.com/images/custom/Octapharma-lockup-01-1@2x.png)
AND USAGE